Ultragenyx Relocates Company Headquarters to Support Operational Expansion
NOVATO, Calif., April 23, 2012 /PRNewswire/ — Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that it has moved its corporate headquarters to a larger facility in the Bel Marin Keys area of Novato, CA. The relocation will accommodate current and future growth of Ultragenyx’ staff and expand operations in the areas of clinical development, regulatory affairs, technical operations, and administration. The company will continue to lease laboratory facilities at the Buck Institute in Novato which currently houses the company’s research staff.
“Our move to our new corporate headquarters will enable us to support the advancement of our pipeline of treatments for rare and ultra-rare diseases and grow our team as needed,” said Emil Kakkis, MD, PhD, Chief Executive Officer, who founded Ultragenyx in 2010. ”We want to express our appreciation to the elected officials and city of Novato for their support of Ultragenyx, and we look forward to continuing to be an integral part of the Novato community.”
Ultragenyx will celebrate the relocation of its corporate headquarters by holding a ribbon-cutting ceremony on Friday, April 27, 2012, at 3:30pm at its new location.
The address of the new corporate headquarters is 60 Leveroni Court, Novato, CA 94949, and the new corporate phone number is 415-483-8800.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.